The CHS / Pfizer Care Until Cure Research Program was established in the year 2000 in collaboration with Wyeth Canada, now Pfizer. Pfizer Canada strives every day to help Canadians live healthy, balanced lives. They do that by discovering and developing innovative medicines. As a company, they’re dedicated to building healthier communities and empowering Canadians to make healthier choices every day. At Pfizer Canada, they believe that to be truly healthy, it takes more than medication.
This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder.
Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization. Grants will be made available for clinical research, including outcome evaluation, in fields relevant to improving the quality of life of:
- persons with hemophilia
- persons with von Willebrand disease or other inherited bleeding disorders
- persons with related conditions such as HIV or hepatitis C infection
- carriers of an inherited bleeding disorder.
For the 2020-2021 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas. The grants review committee will allocate funding to the strongest and most relevant projects included but not limited to the areas of interest listed below.
2020-2021 AREAS OF INTEREST include and are not limited to:
- Hemophilia A or B
1. Epidemiology / burden of disease / outcome research
2. “Real World” observational data / patient reported outcomes to describe the current standard of care or burden of disease
3. Tailoring/Personalized Hemophilia Treatment (eg, prophylaxis regimen, pharmacokinetics, adherence and other factors)
4. The role of extravascular Factor IX in hemostasis
5. Mild Hemophilia: natural history, clinical outcomes, patient reported outcomes, healthcare utilization and cost, quality of life and joint surveillance
6. New considerations in the management of special populations: adolescents, carriers or ageing populations
7. “Real World” observational data on factor utilization and cost-effectiveness
• Clinical monitoring of hemophilia treatment
1. Inhibitors, Inhibitor Management (eg, Immune tolerance), and Immunogenicity
2. Product Switching Experience: clinical and patient reported outcomes, rationale for switch, and clinical monitoring
3. Joint Outcomes and the Role of Point-of-care Joint Ultrasonography in the Management of Hemophilia
• Basic Science of Gene Therapy for Hemophilia
1. Basic science, tropism, transduction efficiency & tolerability of adeno-associated virus (AAV)
2. Epidemiology of AAV seropositivity
3. AAV antibody Titer assessment, reduction, tolerance
4. Role of immunosuppression in managing transaminitis
• Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies
1. Regulation of Coagulation
2. Basic biology of TFPI interactions with Protein C, ATIII, & Protein S
3. Cross talk among regulators interacting with TFPI (e.g. Protein S being a co-factor for both Protein C and TFPI)
4. Role of different TFPI pools in regulation of coagulation
5. Pharmacology resulting from concomitant treatments (especially antifibrinolytics) added to anti-TFPI
• Antifibrinolytic Therapy